logo
Two types of drinks should be avoided before bed on hot nights to help with sleep, scientists say

Two types of drinks should be avoided before bed on hot nights to help with sleep, scientists say

The Journal13-05-2025

LESS COFFEE OR alcohol and cool (not freezing showers) are some of the ways to try to get a decent night's sleep during spells of hot weather.
Sleep quality is being harmed by hotter temperatures, including temperature rise driven by by climate change, and scientists say humans will need to learn how to manage living in warmer conditions.
The human brain is very sensitive to heat, with higher temperatures raising the body's central thermostat and activating stress systems.
Scientists are increasingly exploring mechanisms that can help the body adapt to rising temperatures affecting our sleep and leading to health complications.
'Rising temperatures induced by climate change and urbanisation pose a planetary threat to human sleep, and therefore health, performance, and wellbeing,' according to a 2024 review of scientific literature published in the journal Sleep Medicine.
Armelle Rancillac, a neuroscientist at the Centre for Interdisciplinary Research in Biology, said that to sleep better in a hotter environment, there is a need to 'eliminate or at least pay attention to sleep enemies'.
Before bedtime, it is recommended to take a cool shower (but not an icy one), reduce stimulants like coffee, and limit alcohol, which facilitates falling asleep but slightly raises the internal body temperature.
Avoid hot tubs after a workout, opting instead for outdoor temperatures or a cold bath, said Fabien Sauvet, a researcher at Paris Cite University.
Napping during the hottest hours of the day have also been proven to mitigate the impacts of a sleep deficit.
Short naps — '30 to 40 minutes, and before 2pm' — are ideal, so as not to interfere with a good night's sleep.
In the short term, this can lead to drowsiness, fatigue and a higher risk of accidents at the workplace or on the road.
Advertisement
In the long run, it can create a harmful sleep 'debt', impacting our metabolism and increasing the risk of weight gain, diabetes, cardiovascular diseases and even neurodegenerative diseases like Alzheimer's, Rancillac said.
A sleep deficit can also reduce stress resistance and have a negative impact on mental health.
Humans lost an average of 44 hours of sleep a year during the first two decades of the 21st century compared to earlier periods, according to a 2022 study published in the journal One Earth, which linked the data to rising temperatures.
The intensification of global warming could lead to an annual loss of 50 to 58 hours of sleep per person by 2099, according to research led by Kelton Minor, from the University of Copenhagen, based on data gathered from more than 47,000 individuals in 68 countries.
'Interventional studies and field experiments are now urgently needed to foster adaptation and safeguard the essential restorative role of sleep in a hotter world,' Minor and other authors of the paper said.
Neurons regulating temperature and sleep in the brain are highly interconnected, and lowering the body's internal thermostat is key to improving sleep quality.
Adapting to heat comes at a cost to the body, according to Sauvet.
'We sweat more and faster, for example, but it requires additional hydration. And it has limits, so during heatwaves, the most important thing is to adapt our behaviour,' such as activities, schedules and clothing, Sauvet said.
But humans could 'tolerate higher temperatures than commonly thought', he added, pointing to several studies showing that good sleep quality can be achieved with a room temperature of up to 28 degrees Celsius.
Challenging 'the false belief that the bedroom must be at 18-20C', he said that sleeping in light clothing such as a t-shirt and shorts, and with a simple sheet as well as good ventilation, could help dealing with a few more degrees.
'If we always sleep with air conditioning, we will never acclimatise,' he said.
© AFP 2025

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top doc recommends getting rid of everyday tool to reduce risk of Alzheimer's
Top doc recommends getting rid of everyday tool to reduce risk of Alzheimer's

Irish Daily Mirror

time6 days ago

  • Irish Daily Mirror

Top doc recommends getting rid of everyday tool to reduce risk of Alzheimer's

There is "such positivity" in Alzheimer's research at the moment, says top immunologist Luke O'Neill. A drug that slows down the disease was recently approved by the European Medicines Agency (EMA), and it is hoped that it will be available in Ireland soon. However, the expert stresses that lifestyle changes can help lower a person's chance of developing the disease. Alzheimer's is the most common form of dementia, which is the umbrella term for memory loss and other cognitive abilities that are serious enough to interfere with daily life. It is primarily caused by the build-up of protein deposits in the brain that eventually kills brain cells. While the exact cause of Alzheimer's is unknown, scientists believe that for most people it is caused by a combination of genetic, lifestyle and environmental factors. In July 2024, the Lancet Commission reported that 45 per cent of dementia cases could be prevented by fully addressing 14 lifestyle factors. Here are Luke O'Neill's and the Lancet's lifestyle recommendations on reducing the risk of Alzheimer's- and it includes ditching a tool most of us use daily. Google Maps is a tool that many of us use daily, however, studies suggest that keeping our brains as active as we can can reduces the risk of Alzheimer's. This can be done by learning a new language, doing puzzles, taking part in quizzes and also by navigating new areas and figuring out directions ourselves. A study published in The BMJ in December 2024 found that taxi drivers and ambulance drivers have the lowest rates of death due to Alzheimer's. Other drivers such as airline pilots or bus drivers - those that have predefined routes - did not have a lower risk of developing the disease. This suggests that occupations requiring frequent navigational and spatial processing could offer some protection against Alzheimer's. Social interaction is a great way to keep the mind active, and scientists have identified social isolation as a risk factor for not only Alzheimer's but hypertension and coronary heart disease. Loneliness can be associated with decreased cognitive activity, which can accelerate cognitive decline and poor mood. Professor O'Neill told the Irish Mirror: "A big one is loneliness, that is a risk factor for developing Alzheimer's and Dementia. We have to mind older people, many older people get isolated and with some encouragement we can hopefully diminish the loneliness epidemic that's there." Studies strongly suggest a link between hearing loss and a higher risk of developing dementia. One found that with every 10-dB decrease in hearing ability, there is a 4 per cent to 24 per cent higher risk of developing dementia. Professor O'Neill encourages everyone to be conscious of their hearing and get it checked if they believe it might be declining. He added: "With a hearing aid you can stave that off, so the big message that's been given in the last while is if you are having trouble hearing go and get a hearing aid because it's a risk of getting Alzheimer's. "These are things we can all do at decreasing our own risk of getting it, and they are very optimistic on that front." The newest Lancet Commission study on dementia reported that high LDL cholesterol is associated with a higher risk of dementia. LDL is commonly known as "bad cholesterol", it's a condition where there's excessive amount of LDL cholesterol in the bloodstream. This is usually checked during a routine bloods appointment, often in a GP office. Luckily, much can be done to reduce LDL cholesterol including a balanced diet low in saturated and trans fats. This is usually found in foods like red meat, full-fat dairy, fried foods and processed snacks. Lifelong learning is associated with improved brain health, with higher levels of cognitive activity. This doesn't mean you have to enroll in a degree programme, but learning a new language or taking up a new skill, even casually, can improve brain health. The Lancet Commission found that those who did not complete secondary school education were more at-risk of developing Alzheimer's. Being active is important for a healthier life, and it has been cited as one of the 14 factors that could reduce the risk of dementia. Physical activity can benefit brain health by reducing chronic inflammation, improving blood flow and increasing the release of protein that is good for brain cells. The World Health Organisation recommends that adults get between 150 and 300 minutes of moderate-intensity aerobic physical activity a week. This would include walking briskly, biking, swimming or dancing. It also recommends that on top of this adults should partake in muscle strengthening activities two times a week. Obesity is also a risk factor for developing Alzheimer's disease. However, it's important to note that BMI is not definitive in diagnosing obesity- as some people can have a high percentage of muscle mass. Calculating body fat percentage, or measuring waist-to-hip ratio can be used to determine a healthy body. An analysis published in the National Library of Medicine with over five million people found that those with higher central obesity - measured by waist-to-hip ratio- was associated with a greater risk of cognitive impairment and dementia.

'Hope on horizon' as new drugs tested for Alzheimer's treatment
'Hope on horizon' as new drugs tested for Alzheimer's treatment

RTÉ News​

time03-06-2025

  • RTÉ News​

'Hope on horizon' as new drugs tested for Alzheimer's treatment

Dementia experts have said that "hope is on the horizon" after a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer's disease. Some 138 new treatments are being assessed for the treatment and prevention of Alzheimer's. A third of drugs currently being trialled are "repurposed" medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review. One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia. And four late-stage trials are looking at preventing disease. Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are "only one part of the overall strategy" as they expressed excitement over the variety of new drugs, which are being tested among patients. The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions. Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: "This year has really given us real cause for optimism." She said that as well as more drugs coming through the pipeline, the treatment targets are "more diverse" and "looking at all stages of the disease". She added: "What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating." "This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab." Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: "Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia. "This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments." James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: "What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal." On the drugs which are being investigated for the prevention of disease, Prof Rowe said: "One of the most exciting things of this report is the number of large-scale late-stage trials on prevention. "And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today." He added: "One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years. "The ones that are in trial at the moment are really... bringing forward an effective treatment to earlier stage." For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease. On the repurposing of current drugs, Dr Mead said that it can usually take ten to 15 years for new drugs to be tested and approved for use. "Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases," she said. "A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment." Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an "important first step" in the battle against the disease. The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use. The National Institute for Health and Care Excellence (NICE) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer. Dr Scales added: "Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease. "What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and able to deliver for our patients." She said studies are showing "even more complexities" around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store